Sana Biotechnology results from the phase 1 study using SC291 for the treatment of patients with SLE are expected in 2025.

DelveInsight's 'Lupus Nephritis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline lupus ...

The ACR has released a summary of a new 2024 guideline for the screening, treatment, and management of Lupus Nephritis.

The new guideline also recommends faster tapering to a lower dose of glucocorticoids and a longer duration of ...

A noninvasive urinary biomarker panel predicts lupus nephritis activity and response better than proteinuria, and, if further validated, may aid diagnosis and gauge treatment response, investigators ...

ImmuneOnco Biopharmaceuticals has received approval from China’s National Medical Products Administration for a Phase II ...

Chicago’s Cour Pharmaceuticals—recently honored as one of Fierce Biotech’s 2024 Fierce 15—is bringing its immunology mission ...

The glucose-lowering and weight-reducing drug class appears to benefit the heart and kidneys in people with lupus and lupus nephritis, independently of glucose-lowering and weight loss.

Fast Track designation is designed to expedite clinical development and regulatory review timelinesEnrolling patients in the GLEAM trial for ...

This report report provides comprehensive insights about 30+ companies and 35+ pipeline drugs in Lupus Nephritis pipeline landscape. It covers the pipeline drug profiles, including clinical and ...

Two studies presented at the 2024 American College of Rheumatology (ACR) Annual Meeting revealed that GLP-1 receptor agonists ...